Ocular Therapeutix (OCUL) Expected to Announce Earnings on Tuesday

Key Points

• Ocular Therapeutix (OCUL) is expected to announce its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($0.35) per share and revenue of $13.12 million.
• The stock is currently trading at $11.75, reflecting a 2.7% decline, with a market cap of $1.87 billion and an average analyst rating of "buy" with a price target of $17.33.
• Insider trading activity includes Director Richard L. Md Lindstrom purchasing 10,000 shares at $6.96 each, indicating increased confidence, while insider Pravin Dugel sold 21,219 shares at an average price of $7.18.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect Ocular Therapeutix to post earnings of ($0.35) per share and revenue of $13.12 million for the quarter.

Ocular Therapeutix Trading Up 0.8%

NASDAQ:OCUL traded up $0.09 during trading hours on Friday, hitting $11.67. The stock had a trading volume of 181,148 shares, compared to its average volume of 1,745,495. Ocular Therapeutix has a one year low of $5.78 and a one year high of $12.35. The company has a debt-to-equity ratio of 0.26, a quick ratio of 10.14 and a current ratio of 10.22. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -10.15 and a beta of 1.43. The business's 50 day moving average is $9.53 and its 200-day moving average is $8.18.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Needham & Company LLC lowered their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. William Blair assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an "outperform" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Ocular Therapeutix has a consensus rating of "Buy" and an average target price of $17.33.

Insider Activity at Ocular Therapeutix

In related news, Director Richard L. Md Lindstrom purchased 10,000 shares of Ocular Therapeutix stock in a transaction dated Thursday, May 8th. The stock was bought at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the acquisition, the director directly owned 172,704 shares of the company's stock, valued at $1,202,019.84. This represents a 6.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Pravin Dugel sold 21,219 shares of the company's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the transaction, the insider owned 3,499,099 shares of the company's stock, valued at $25,123,530.82. This trade represents a 0.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,079 shares of company stock valued at $208,739 in the last quarter. Corporate insiders own 2.30% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Ocular Therapeutix stock. Caxton Associates LLP bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 33,821 shares of the biopharmaceutical company's stock, valued at approximately $248,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.